Table 1: Here
The mean score of EORTC QLQ of patients allocated to silymarin treatment was 94.07 ± 6.65, whereas it was 93.02 ± 7.16 in the placebo group. The mean final EORTC QLQ was 94.47 ±7.32 in the intervention group and 92.42 ±8.39 in the comparison group. In the present study, analysis of covariance showed that the mean differences of EORTC QLQ in the intervention group improved 1.06 times more than the comparison group, but this difference was not statistically significant (p-value = 0.4) (Table 2).